{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e28e0d8963f166217546493/679a471ca7ace681d864ee2d?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Would Wider Access to GLP-1s Throttle Addiction?","description":"<p>Drugs like Ozempic show potential to help those with addiction with little downside risk. How quickly can their availability be expanded? Nicholas Reville of <a href=\"https://www.caspr.org/\" target=\"_blank\" rel=\"noopener noreferrer\">CASPR</a> makes his case.</p>","author_name":"Cato Institute"}